balance equationreview2018-12-31
Difference 84000000 exceeds tolerance 22430000.000. Presentation or filing-vintage differences need review.
Revenue
$21.31B
Fiscal year ended 2025-12-31Operating income
$3.51B
Fiscal year ended 2025-12-31Free cash flow
$2.53B
Fiscal year ended 2025-12-31TENET HEALTHCARE CORP (THC) reported revenue of $21.31B for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from TENET HEALTHCARE CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-General Medical & Surgical Hospitals, NEC.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.31B | $20.68B | $20.56B | $19.17B | $19.48B | $17.64B | $18.48B | $18.31B | $19.18B | $19.62B |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | $3.51B | $5.96B | $2.51B | $2.33B | $2.87B | $1.99B | $1.54B | $1.64B | $1.11B | $1.25B |
| Net income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 90.83M | shares 97.88M | shares 104.80M | shares 110.52M | shares 108.57M | shares 106.26M | shares 103.40M | shares 103.88M | shares 100.59M | shares 99.32M |
| Pretax income | $2.80B | $5.25B | $1.62B | $1.34B | $1.89B | $671.00M | $320.00M | $629.00M | -$101.00M | $248.00M |
| Income tax expense | $433.00M | $1.18B | $306.00M | $344.00M | $411.00M | -$97.00M | $160.00M | $173.00M | $219.00M | $67.00M |
| Diluted EPS | $15.49 | $32.70 | $5.71 | $3.79 | $8.42 | $3.75 | $-2.08 | $1.00 | $-7.00 | $-1.93 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.88B | $3.02B | $1.23B | $858.00M | $2.36B | $2.45B | $262.00M | $411.00M | $611.00M | $716.00M |
| Total assets | $29.68B | $28.94B | $28.31B | $27.16B | $27.58B | $27.11B | $23.36B | $22.43B | $23.38B | $24.70B |
| Current assets | $7.85B | $7.68B | $7.17B | $5.98B | $7.08B | $7.15B | $5.08B | $4.64B | $5.57B | $5.26B |
| Total liabilities | $20.70B | $20.39B | $22.80B | $22.55B | $23.32B | $24.22B | $21.42B | $20.30B | $20.98B | $21.23B |
| Current liabilities | $4.46B | $4.31B | $4.76B | $4.48B | $5.11B | $4.85B | $4.20B | $3.86B | $4.33B | $4.03B |
| Total equity incl. NCI | $6.02B | $5.82B | $3.12B | $2.46B | $2.05B | $937.00M | $437.00M | $624.00M | $483.00M | $1.08B |
| Temporary (mezzanine) equity | $2.96B | $2.73B | $2.39B | $2.15B | $2.20B | $1.95B | $1.51B | $1.42B | $1.87B | $2.39B |
| Inventory | $348.00M | $346.00M | $411.00M | $405.00M | $384.00M | $368.00M | $310.00M | $305.00M | $289.00M | $326.00M |
| Accounts receivable | $2.56B | $2.54B | $2.91B | $2.94B | $2.77B | $2.69B | $2.74B | $2.60B | $2.62B | $2.90B |
| Goodwill | $11.20B | $10.69B | $10.31B | $10.12B | $9.26B | $8.81B | $7.25B | $7.28B | $7.02B | $7.42B |
| Long-term debt | $13.09B | $13.08B | $14.88B | $14.93B | $15.51B | $15.57B | $14.58B | $14.64B | $14.79B | $15.06B |
| Accounts payable | $1.36B | $1.29B | $1.41B | $1.50B | $1.30B | $1.21B | $1.20B | $1.21B | $1.18B | $1.33B |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.54B | $2.05B | $2.37B | $1.08B | $1.57B | $3.41B | $1.23B | $1.05B | $1.20B | $558.00M |
| Capital expenditures | $1.01B | $931.00M | $751.00M | $762.00M | $658.00M | $540.00M | $670.00M | $617.00M | $707.00M | $875.00M |
| Investing cash flow | -$1.28B | $3.43B | -$969.00M | -$808.00M | -$714.00M | -$1.61B | -$619.00M | -$115.00M | $21.00M | -$430.00M |
| Financing cash flow | -$2.40B | -$3.68B | -$1.04B | -$1.78B | -$936.00M | $385.00M | -$763.00M | -$1.13B | -$1.33B | $232.00M |
| Net change in cash | -$136.00M | $1.79B | $370.00M | -$1.51B | -$82.00M | $2.18B | -$149.00M | -$200.00M | -$105.00M | $360.00M |
| Stock-based compensation | $104.00M | $67.00M | $66.00M | $56.00M | $56.00M | $44.00M | $42.00M | $46.00M | $59.00M | $68.00M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $1.39B | $672.00M | $200.00M | $250.00M | $0 | $0 | Unavailable | Unavailable | $0 | $0 |
| Depreciation & amortization | $863.00M | $818.00M | $870.00M | $841.00M | $855.00M | $857.00M | $850.00M | $802.00M | $870.00M | $850.00M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $2.53B | $1.12B | $1.62B | $321.00M | $910.00M | $2.87B | $563.00M | $432.00M | $493.00M | -$317.00M |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | 16.5% | 28.8% | 12.2% | 12.2% | 14.7% | 11.3% | 8.3% | 8.9% | 5.8% | 6.4% |
| FCF margin | 11.9% | 5.4% | 7.9% | 1.7% | 4.7% | 16.3% | 3.0% | 2.4% | 2.6% | -1.6% |
| SBC / revenue | 0.5% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% | 0.3% | 0.3% | 0.3% |
| Current ratio | 1.76x | 1.78x | 1.51x | 1.34x | 1.38x | 1.47x | 1.21x | 1.20x | 1.29x | 1.30x |
| Revenue YoY growth | 3.1% | 0.5% | 7.2% | -1.6% | 10.5% | -4.5% | 0.9% | -4.5% | -2.3% | Unavailable |
| Net margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 4.7% | 4.5% | 3.7% | 4.0% | 3.4% | 3.1% | 3.6% | 3.4% | 3.7% | 4.5% |
| Long-term debt / equity | 2.18x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 15.5% | 22.6% | 18.9% | 25.6% | 21.8% | -14.5% | 50.0% | 27.5% | Unavailable | 27.0% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open THC in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-04-29View SEC filing
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2017-12-31
Difference 56000000 exceeds tolerance 23385000.000. Presentation or filing-vintage differences need review.